학술논문

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
Document Type
Article
Source
In ESMO Open April 2021 6(2)
Subject
Language
ISSN
2059-7029